YIH
MRSN

Y-Intercept (HK)’s Mersana Therapeutics MRSN Stock Holding History

Y-Intercept (HK)’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,871
Closed -$94K – 1612
2024
Q2 		$94K Buy
+1,871
New +$135K 0.01% 1263
2023
Q4 		– Sell
-1,809
Closed -$57.4K – 1495
2023
Q3 		$57.4K Buy
1,809
+1,343
+288% +$63.8K 0.01% 992
2023
Q2 		$38.3K Buy
+466
New +$68.2K ﹤0.01% 1208

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Y-Intercept (HK)'s MRSN Position: Q3 2024 in Review

Y-Intercept (HK) sold out of Mersana Therapeutics (MRSN) in Q3 2024, closing a stake of 1,871 shares — an estimated $94K sold.

Y-Intercept (HK) first reported a position in MRSN in Q2 2023 and held it in 3 quarters. The position peaked at $94K in Q2 2024. 113 funds tracked by Wall St. Rank hold MRSN as of Q3 2024.

  • Y-Intercept (HK) reported no remaining Mersana Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 1,871 Mersana Therapeutics shares in Q3 2024, an estimated $94K.
  • Y-Intercept (HK) first reported a position in Mersana Therapeutics in Q2 2023 and held it in 3 quarters.
  • Y-Intercept (HK)'s Mersana Therapeutics position peaked at $94K in Q2 2024.
  • 113 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2024.

Based on Y-Intercept (HK)'s 13F filing for Q3 2024, filed 15 Nov 2024.